Curanex Pharmaceuticals Inc CURX
6.00 USD -0.19 (-3.07%)
Nov 4, 2026, 1:23 PM EST
5.60 Day range 6.06
3.58 52-week range 13.36
- YTD
- -9.37%
- 1 year
- -50.00%
Financial health
Altman Z-Score
10.48 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B-2 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 4
Valuation
P/E -2.2×
FY 2022 5y median -2908× FY 2025
P/S 0.0×
FY 2022 5y median 0.0× FY 2025
P/B 0.8×
FY 2022 5y median 111× FY 2025
P/FCF -0.9×
FY 2022 5y median -101× FY 2025
EV/EBITDA -1.1×
FY 2022 5y median -192× FY 2025
EV/Sales 0.0×
FY 2022 5y median 0.0× FY 2025
FCF Yield -111.9%
FY 2022 5y median -0.2% FY 2025
Profitability
Gross Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2022 5y median 0.0% FY 2025
ROE -37.7%
FY 2022 5y median -34.8% FY 2025
ROIC -36.7%
FY 2022 5y median -34.4% FY 2025
ROA -36.5%
FY 2022 5y median -31.2% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2022 FY 2025
Operating Income -1061.2%
FY 2022 FY 2025
EPS (diluted) -1046.2%
FY 2022 FY 2025
Free Cash Flow -1787.1%
FY 2022 FY 2025
Financial Health
Current Ratio 81.9×
FY 2022 5y median 20.4× FY 2025
Quick Ratio 81.9×
FY 2022 5y median 20.4× FY 2025
Debt / Equity 0.0×
FY 2022 5y median 0.0× FY 2025
Net Debt / EBITDA 1.1×
FY 2022 5y median 0.8× FY 2025
Interest Coverage -497×
FY 2022 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2022 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2022 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31